- Home
- UTF vs SLS Comparison
UTF vs SLS Comparison
Compare UTF & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UTF | SLS |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2004 | 2007 |
Fundamental Metrics
Financial Performance| Metric | UTF | SLS |
|---|---|---|
| Price | $25.62 | $9.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 357.3K | ★ 4.5M |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.42 | $1.39 |
| 52 Week High | $28.11 | $15.88 |
Technical Indicators
Market Signals| Indicator | UTF | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 34.83 |
| Support Level | $25.44 | $9.19 |
| Resistance Level | $27.29 | $12.53 |
| Average True Range (ATR) | 0.29 | 0.73 |
| MACD | 0.15 | -0.06 |
| Stochastic Oscillator | 88.18 | 4.06 |
Price Performance
Historical ComparisonAbout UTF Cohen & Steers Infrastructure Fund Inc
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. Under normal market conditions, the fund invests the majority of its managed assets in securities issued by infrastructure companies, which consist of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.